the effect of prostaglandins F2a on Complete removal of myoma type 1 and type 2

the effect of prostaglandins F2a on Complete removal of myoma during hysteroscopic myomectomy in women With Type 1 and 2 myoma

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150909023949N8

Enrollment

Registered

2018-02-03

Start date

2017-01-03

Completion date

Unknown

Last updated

2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uterin fibroma. Obstetric and gynaecological devices associated with adverse incidents

Interventions

Intervention 1: treatment group:F2A prostaglandin injection during surgery. Intervention 2: Control group: : A surgical procedure without injection of prostaglandin F2A.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: patients with myoma of sub-mucosal type 1 and 2 normal papsmir abnormal uterine bleeding if endometrial biopsy or curettage normal pre-ups of patients with normal anesthesia

Exclusion criteria

Exclusion criteria: myoma of sub-mucosal higher than type 2 uterine cancer malignant or premalignant lesions of the cervix sensitivity to prostaglandins pelvic infection infection of the cervix vaginal infections active liver disease, renal, cardiac and pulmonary previous caesarean section or major uterine surgery alcohol 24 hours ago

Design outcomes

Primary

Measure	Time frame
There remnant of myoma. Timepoint: 3 months after surgery. Method of measurement: vaginal sonogeraphy.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMansoureh Vahdat

Iran University of Medical Sciences

mansoureh_vahdat@yahoo.com+98 21 6650 9283

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026